Institut Straumann AG

Development of dental implant systems and oral tissue regeneration products

The Institut Straumann AG has its origins in “Dr. Ing. R. Straumann Research Institute AG” established in 1954 in Waldenburg, Switzerland. Close contacts exist with the International Team for Implantology (ITI). The company has a second production site in Villeret and, following the acquisition of Kuros Therapeutics AG, has turned to biomaterials and tissue regeneration. Straumann AG has been headquartered in Basel since 2004.

Gilbert Achermann, President, CEO
Marco Gadola, CFO, Finance Division

Rudolf Maag, Dr.h.c., Chairman
Oskar Ronner, Vice Chairman
Dr Sebastian Burckhardt
Dominik Ellenrieder
Jürg Morant
Thomas Straumann, Dr.h.c.

Peter Merian-Weg 12
4052 Basel
Switzerland
Phone: +41-61-965-11-11
Fax: +41-61-965-11-01

Straumann AG focuses predominantly on dental implants, but has in recent years attached greater importance to exploring oral tissue regeneration. The copany’s product portfolio contains Emdogain®, Bone Ceramic and Bone Block Fixation, an extensive “toolbox” for dental professionals.

Emdogain® is a biological product creating an insoluble matrix that allows selective cell colonisation, in which cellular interactions lead to cell proliferation, growth factor synthesis and cell differentiation, i.e. stimulation of the regeneration of hard and soft tissues, e.g. in periodontal diseases like intrabony defects, class II mandibular furcation and recession defects.

Bone Ceramic is a synthetic bone substitute based on porous material that advances the regrowth of vital bone.

Bone Block Fixation targets the stabilisation and fixation of bone grafts and bone filling materials in order to support implant procedures.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.